

Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer

Komal L. Jhaveri¹, Meritxell Bellet², Nicholas C. Turner³, Sherene Loi⁴, Aditya Bardia⁵, Valentina Boni^{6*}, Joohyuk Sohn⁷, Tomas G. Neilan⁸, Rafael Villanueva-Vázquez⁹, Peter Kabos¹⁰, Laura García-Estévez¹¹, Elena López-Miranda¹², J. Alejandro Pérez-Fidalgo¹³, Jose M. Pérez-García¹⁴, Jiajie Yu¹⁵, Jill Fredrickson¹⁶, Heather M. Moore¹⁷, Ching-Wei Chang¹⁸, John W. Bond^{19†}, Jennifer Eng-Wong¹⁶, Mary R. Gates¹⁶, and Elgene Lim²⁰

¹Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, and Weill Cornell Medical College, New York, New York.

²Breast Cancer Unit, Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. ³Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. ⁴Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, and The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia. ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ⁶START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain. ⁷Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. ⁸Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. ⁹Institut Català d'Oncologia, l'Hospitalet–Hospital Duran i Reynals, Barcelona, Spain. ¹⁰School of Medicine, University of Colorado, Aurora, Colorado. ¹¹Breast Cancer Department, MD Anderson Cancer Center Madrid, Madrid, Spain. ¹²Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. ¹³Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain. ¹⁴International Breast Cancer Center (IBCC),

Pangaea Oncology, Quiron Group, Barcelona, Spain and Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. ¹⁵Clinical Pharmacology, Genentech, Inc., South San Francisco, California. ¹⁶Genentech Research and Early Development (gRED), Genentech, Inc., South San Francisco, California. ¹⁷Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. ¹⁸PHC and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, California. ¹⁹Product Development Safety, Genentech, Inc., South San Francisco, California. ²⁰St Vincent's Hospital and Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia.

* Current affiliation: Next Oncology, University Hospital Quirónsalud Madrid, Madrid, Spain.

† Current affiliation: Gilead Sciences, Foster City, California.

Running Title: Ph Ia/b Giredestrant ±Palbociclib ±LHRH in ER+ HER2– LA/mBC (59/60 characters, including spaces)

Abbreviations List: AE, adverse event; AI, aromatase inhibitor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BC, breast cancer; bpm, beats per minute; CBR, clinical benefit rate; CCOD, clinical cutoff date; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; CR, complete response; CRF, case report form; ctDNA, circulating tumor DNA; D, day; DLT, dose-limiting toxicity; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; ER+, estrogen receptor-positive; *ESR1m*, *ESR1* mutant; ET, endocrine therapy; FES [¹⁸F]-fluoroestradiol, [¹⁸F]-fluoroestradiol positron emission tomography; H, hour; HER2–, HER2-negative; HR, heart rate; IEC, Independent Ethics Committee; IRB, Institutional Review Board; LHRH, luteinizing hormone-releasing hormone; MAD, maximum administered dose; MTD, maximum tolerated dose; NA, not assessed; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NE, not evaluable; NON, non-complete response/non-disease progression; NOS, not otherwise specified; ORR, objective response

rate; PD, disease progression; PO, oral; PR, partial response; Q4W, once every 4 weeks; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors; SAE, serious adverse event; SD, stable disease; SERD, selective estrogen receptor antagonist and degrader; SERM, selective estrogen receptor modulator.

Corresponding Author Details: Komal L. Jhaveri, Department of Medicine

Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center, 300 East 66th Street, 8th floor, New York, NY 10065. Phone: 646 888 5145. E-mail: jhaverik@mskcc.org.

Conflict of Interest Disclosure Statement:

K.L. Jhaveri has a consultant/advisory board role in Novartis, Pfizer, Bristol Myers Squibb, Jounce Therapeutics, Taiho Oncology, Genentech, Inc., AbbVie, Eisai, AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Sun Pharma Advanced Research Company Ltd, Gilead, Seattle Genetics, Olema Pharmaceuticals, Menarini/Stemline, Scorpion Therapeutics, and Lilly/Loxo Oncology; and has received research funding from Novartis, Clovis Oncology, Genentech, Inc., AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals/Loxo Oncology, Zymeworks, Gilead, Puma Biotechnology, Context Therapeutics, Scorpion Therapeutics, and Merck Pharmaceuticals.

M. Bellet has a consultant/advisory board role in Pfizer, Novartis, Eli Lilly, and Stemline Menarini; an honorary role (speaking for Pfizer, Novartis, and Eli Lilly); and has received travel/inscription/accommodation funding from Pfizer.

N.C. Turner has received advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche/Genentech, Inc., Novartis, GlaxoSmithKline, Repare Therapeutics, Relay Therapeutics, Zentalis, Gilead, Inivata, Guardant, and Exact Sciences; and research funding from AstraZeneca, Pfizer, Roche/Genentech, Merck Sharp & Dohme, Guardant Health, Inivata, Inivata, Personalis, and Natera.

S. Loi receives research funding to her institution from Novartis, Bristol Myers Squibb, MSD, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca/Daiichi-Sankyo, and Seattle Genetics; has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Myers Squibb, MSD, AstraZeneca/Daiichi-Sankyo, Eli Lilly, Pfizer, Gilead Therapeutics, Nektar Therapeutics, Puma Biotechnology and Roche-Genentech; and has acted as consultant (paid to her institution) to Novartis, GlaxoSmithKline, Roche/Genentech, AstraZeneca/Daiichi-Sankyo, Pfizer, Gilead Therapeutics, Seattle Genetics, MSD, Tallac Therapeutics, Eli Lilly, and Bristol Myers Squibb.

A. Bardia reports consulting/advisory roles for Novartis, Genentech, Inc./F. Hoffmann-La Roche Ltd, Pfizer, Biotheranostics, Merck, Radius Health/Menarini, Immunomedics/Gilead, Sanofi, Puma Biotechnology, Daiichi Sankyo/AstraZeneca, Eli Lilly, and Mersana; and institutional research funding from Genentech, Inc., Novartis, Pfizer, Merck, Sanofi, Radius Health/Menarini, Immunomedics/Gilead, Daiichi Sankyo/AstraZeneca, and Eli Lilly.

V. Boni is the Director of Clinical Cancer Research, NEXT Madrid, University Hospital Quirónsalud Madrid, Madrid, Spain; has a consultant/advisory role in Puma Biotechnology, Ideaya Biosciences, Loxo Therapeutics, CytomX Therapeutics, Guidepoint, Oncoart, and IDMC Nanobiotix NANORAY-312, and has participated in a Steering Committee for CytomX Therapeutics; has an honorary role (speaking) in Eli Lilly, and MSD; has received travel/inscription/accommodation funding from Bayer (ESMO GI); and has also received institutional financial support for clinical trials from AbbVie, ACEO, Adaptimmune, Amcure, AMGEN, Amunix, AstraZeneca, Bristol Myers Squibb, CytomX, GSK, Genentech/Roche, H3, Incyte, Janssen, Kura, Lilly, Loxo, Nektar, MacroGenics, Menarini, Merck, Merus, Nanobiotix, Novartis, Pfizer, PharmaMar, Principia, Puma, Sanofi, Taiho, Tesaro, BeiGene, Transgene, Takeda, Inovio, MSD, PsiOxus, Seattle Genetics, Mersana, Daiichi Sankyo, Astellas, ORCA, Boston Therapeutics, Dynavax, Debiopharm, Boehringer Ingelheim, Regeneron, Millennium, Synthon, Spectrum, Rigontec, and Zenith.

T.G. Neilan holds the Michael and Kathryn Park Chair in Cardiology and was also supported, in part, through a kind gift from A. Curtis Greer and Pamela Kohlberg, Christina and Paul

Kazilionis, and a Hassenfeld Scholar Award; is also supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute grants (R01HL130539, R01HL137562, K24HL150238); has received advisory fees from AbbVie, CRC Oncology, C4 Therapeutics, H3-Biomedicine, Genentech, Inc., Roche, Sanofi, Bristol Myers Squibb, and Intrinsic Imaging; and has received grant funding from AstraZeneca and Bristol Myers Squibb.

R. Villanueva-Vázquez has received advisory fees from Lilly and AstraZeneca; and has received travel/inscription/accommodation funding from Novartis, Lilly, AstraZeneca, Daiichi Sankyo, and Eisai.

P. Kabos has received research funding from Genentech, Inc., AstraZeneca, Eli Lilly, Menarini/Stemline, HiberCell, Inc., and Sanofi.

L. García-Estévez has a consultant/advisory board role in Roche Pharma, Eisai, Daiichi Sankyo, Gilead, and Seattle Genetics; and has received research funding from Roche Pharma.

E. López-Miranda has a consultant/advisory board role in Roche, AstraZeneca, and Daiichi Sankyo; and has received travel, inscription, and accommodation funding from Roche.

J.A. Pérez-Fidalgo has a consulting/advisory role in Ability Pharma, Roche, Amgen, Tesaro, AstraZeneca, Clovis Oncology, GSK; speakers' bureau with Roche, Pfizer, AstraZeneca Spain, Novartis, Ipsen, PharmaMar, GSK, Clovis, and Seagen; has received research funding to his institution from GSK, PharmaMar, and AstraZeneca Spain; has a patent pending; has received travel, accommodations, and/or expenses from Roche, Pfizer, AstraZeneca, and GSK; and has uncompensated relationships with AstraZeneca Spain and Novartis.

J.M. Pérez-García has a consultant/advisory board role in Roche, Lilly, Eisai, AstraZeneca, Daiichi Sankyo, Gilead, and Seattle Genetics; and has received travel, inscription, and accommodation funding from Roche.

J. Yu is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.

J. Fredrickson is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.

H.M. Moore is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.
C.-W. Chang is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.
J.W. Bond was employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.
J. Eng-Wong is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.
M.R. Gates is employed by Genentech, Inc. and has stocks in F. Hoffmann-La Roche Ltd.
E. Lim reports research support from Ellipses, Novartis, and Pfizer; speaker compensation (paid to institution) from AstraZeneca, Gilead, Novartis, Lilly, Pfizer and Roche; meeting and/or travel support from AstraZeneca, Novartis, and Gilead; advisory board compensation (paid to institution) from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer and Roche; and leadership or fiduciary roles in the Breast Cancer Trials and University of New South Wales.
All authors received research support in the form of third-party medical writing assistance from F. Hoffmann-La Roche Ltd.

Authors' Contributions

- Conceptualization: KLJ, AB
- Resources: N/A
- Data curation: JY
- Software: N/A
- Formal analysis: JE-W, JY, HMM, C-WC, JF, JB
- Supervision: JE-W, JY, KLJ
- Funding acquisition: N/A
- Validation: N/A
- Investigation: JY, HMM, KLJ, JF, SL, EL-M, MB, VB, AB, JAPF
- Visualization: JY, HMM, JF
- Methodology: JY, JE-W, JB
- Writing – original draft: HMM, C-WC, JWB, JE-W, JY, MRG, TGN, KLJ, JB, AB
- Project administration: N/A
- Writing-review and editing: All authors

- Other detailed descriptions:
 - All authors gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
 - Data acquisition: JE-W, JY, HMM, JF, JMP-G, EL, RV-V, PK, SL, JS, MRG, LG-E, MB, VB, JAPF, NCT
 - Data interpretation: JE-W, JY, HMM, JF, TGN, JMP-G, EL, RV-V, PK, SL, MRG, JB, MB, VB, NCT

Word Count: 5,546/5,000 max (excl. references, tables and figure legends)

Figures and Tables: 6/6 max

References: 50/50 max

Supplementary: 8/8 max

Disclosure of prior presentation:

This study has been presented in part:

Jhaveri KL, Winer EP, Lim E, et al. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer. Poster presentation at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA; December 10–14, 2019; Abstract PD7-05.

Lim E, Jhaveri KL, Perez-Fidalgo JA, et al. A Phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. Poster presentation at the American Society of Clinical Oncology virtual congress; May 29–31, 2020; Abstract 1023.

Jhaveri KL, Boni V, Sohn J, et al. Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). Poster presentation at the American Society of Clinical Oncology virtual congress; June 4–8, 2021; Abstract 1017.

Turner N, Loi S, Moore H, et al. Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2–LA/mBC). Poster presentation at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA; December 7–10, 2021; Abstract PD13-07.

Neilan T, Vázquez RV, Bellet T, et al. Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Poster presentation at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA; December 7–10, 2021; Abstract P5-18-07.

Translational Relevance (137/120–150 words)

Endocrine therapy (ET) is a mainstay of estrogen receptor-positive breast cancer (ER+ BC) treatment; however, resistance to current standard-of-care ETs remains a key limitation, with *ESR1* mutations being an important mechanism of resistance. Moreover, available ETs can be associated with adverse events (that reduce treatment adherence) and/or may lack a more convenient oral formulation. Therefore, new ETs with oral dosing, acceptable safety profiles, increased antitumor activity, and the ability to overcome resistance are needed to prolong survival of patients with ER+ BC. The primary analysis of the phase Ia/b GO39932 study demonstrated that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader, is well tolerated and potentially clinically active as a single agent and in combination with palbociclib for the treatment of patients who have disease progression on prior ETs, including in patients with *ESR1*-mutated tumors.

Abstract (244/250 words)

Purpose: Giredestrant is an investigational next-generation oral selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor-positive (ER+) breast cancer. We present the primary analysis results of the phase Ia/b GO39932 study (NCT03332797).

Patients and Methods: Patients with ER+, HER2-negative locally advanced/metastatic breast cancer previously treated with endocrine therapy received single-agent giredestrant (10, 30, 90, or 250 mg), or giredestrant (100 mg) ±palbociclib 125 mg ±luteinizing hormone-releasing hormone (LHRH) agonist. Detailed cardiovascular assessment was conducted with giredestrant 100 mg. Endpoints included safety (primary), pharmacokinetics, pharmacodynamics, and efficacy.

Results: As of January 28, 2021, with 175 patients enrolled, no dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. Adverse events (AEs) related to giredestrant occurred in 64.9% and 59.4% of patients in the single-agent ±LHRH agonist and giredestrant +palbociclib ±LHRH agonist cohorts, respectively (giredestrant-only related grade 3/4 AEs were reported in 4.5% of patients across the single-agent cohorts and 3.1% of those with giredestrant +palbociclib). Dose-dependent asymptomatic bradycardia was observed, but no clinically significant changes in cardiac-related outcomes: heart rate, blood pressure, or exercise duration. Clinical benefit was observed in all cohorts (48.6% of patients in the single-agent cohort and 81.3% in the giredestrant +palbociclib ±LHRH agonist cohort), with no clear dose relationship, including in patients with *ESR1*-mutated tumors.

Conclusions: Giredestrant was well tolerated and clinically active in patients who progressed on prior ET. Results warrant further evaluation of giredestrant in randomized trials in early- and late-stage ER+ breast cancer.

Introduction

Breast cancer is the most common cancer type worldwide (1). Around 70%–80% of cases are estrogen receptor-positive (ER+) (2, 3), most are driven by ER activity for tumor growth and progression, and endocrine therapy (ET) is a treatment mainstay. Standard-of-care ETs include aromatase inhibitors (AIs), e.g., anastrozole, which block estradiol synthesis; selective ER modulators (SERMs), e.g., tamoxifen, which antagonize estradiol effects via competitive binding to ERs; and selective ER antagonists and degraders (SERDs), e.g., the first-generation agent fulvestrant, which fully antagonize and degrade ERs (4). Combining fulvestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), e.g., palbociclib, ribociclib, or abemaciclib, improves outcomes, as shown in the phase III studies PALOMA-3, MONALEESA-3, and MONARCH-2, respectively (5-7). Currently approved ETs have limitations, including resistance development during/after treatment (8, 9). Resistance to AIs may result from acquisition of mutations in *ESR1* (10), the gene that encodes ER, which drives constitutive estrogen-independent transcription and proliferation (11, 12). The high prevalence of *ESR1*-mutated tumors among patients in the metastatic setting is associated with selective treatment pressure with AIs (13, 14). *ESR1* mutations, e.g., Y537S, also drive resistance to fulvestrant and several SERMs, including tamoxifen (11). Furthermore, the widely used SERD fulvestrant is given as an intramuscular injection, which limits clinical acceptability (4, 15-17), and has poor efficacy in patients previously treated with CDK4/6is (18, 19). In addition, ET adherence may be decreased by associated adverse events (AEs) and their subsequent impact on patients' quality of life (20, 21).

Despite becoming refractory to currently available ETs, most tumors remain ER signaling-dependent, and patients with ER+ breast cancer may respond to second-/third-line ET after progression on previous therapies (22, 23). Therefore, there is an unmet need for new, orally available, ER-targeting therapies with acceptable safety profiles that delay disease progression (PD) and overcome resistance, which may thus prolong survival.

Giredestrant is a highly potent, nonsteroidal oral SERD that binds to the ER ligand binding domain, outcompeting estrogen and causing intranuclear ER immobilization prior to its

degradation (24). Giredestrant achieves robust ER occupancy, is well tolerated alone and in combination with palbociclib, and shows encouraging activity regardless of *ESR1* mutation status (25-29).

We present the primary analysis of the phase Ia/b GO39932 study (NCT03332797), which evaluated giredestrant as a single agent or in combination with palbociclib in patients with ER+, HER2-negative (HER2-) locally advanced/metastatic breast cancer.

Materials and Methods

Study design

GO39932 is an ongoing (with some patients still receiving study treatment), phase Ia/Ib, multicenter, open-label study conducted at 23 sites in five countries: Australia, Spain, UK, USA, Republic of Korea. Patients were enrolled in two stages (**Fig. 1**). First, a single-agent dose-escalation stage was enrolled to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), which included multiple pharmacokinetic timepoint collections. Once the single-agent MTD/MAD was established, the following cohorts were included: backfill single-agent escalation cohorts (≤ 7 patients) to collect additional pharmacokinetic, pharmacodynamic, and response data, at dose levels that had been shown not to exceed MTD; dose-expansion stage cohorts to acquire additional pharmacokinetic, pharmacodynamic, and safety data with giredestrant at or below MTD/MAD as a single agent (\pm luteinizing hormone-releasing hormone [LHRH] agonist) or in combination with palbociclib (\pm LHRH agonist).

GO39932 was conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, the International Council for Harmonisation Good Clinical Practice guidelines, or applicable laws and regulations of each country where the research was conducted if they provided greater protection to the individual. All patients provided written informed consent. The protocol, protocol amendments, informed consent form, Investigator Brochure, and other relevant documents (e.g., advertisements) were submitted to an Institutional Review Board

(IRB)/Independent Ethics Committee (IEC) by the investigator and reviewed and approved by the IRB/IEC before the study was initiated. Any amendments to the protocol required IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.

Patient eligibility

Key eligibility criteria were: histologically/cytologically proven diagnosis of adenocarcinoma of the breast; evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent or with metastatic disease; locally assessed ER-positivity (staining in $\geq 1\%$ cells by immunohistochemistry) and HER2-negativity (per American Society of Clinical Oncology/College of American Pathologists) (30, 31); locally advanced/metastatic breast cancer that had recurred/progressed while being treated with adjuvant ET for ≥ 24 months and/or ET in the incurable/locally advanced/metastatic setting and derived a clinical benefit from ET (tumor response/stable disease for ≥ 6 months); ≤ 2 prior lines of treatment for locally advanced/metastatic breast cancer; ≥ 2 weeks elapsed from the use of any other ET/targeted therapy/chemotherapy; and postmenopausal women (pre-/perimenopausal women simultaneously received LHRH agonists with giredestrant 100 mg). Key exclusion criteria were: known brain metastases that were untreated/symptomatic/required therapy to control symptoms; serious medical conditions/clinically significant abnormalities detected in clinical laboratory tests that precluded the patient's safe participation in and completion of the study; abnormal electrocardiogram, including complete left bundle branch block/second-/third-degree heart block/evidence of prior myocardial infarction; ongoing treatment with medications that prolong the QT interval; and, in a cardiac evaluation cohort (detailed below), ongoing treatment with medications that decrease heart rate (HR), including beta blockers. In the giredestrant 100 mg +palbociclib 125 mg \pm LHRH agonist cohorts, no prior treatment with a CDK4/6i was allowed; however, prior treatment with these drugs was allowed in the cardiac evaluation cohort.

Procedures

In the single-agent dose-escalation stage, increasing doses of once-daily (QD) giredestrant were tested on days 1–28 of each 28-day cycle: 10 mg, 30 mg, 90 mg, or 250 mg. Patients were sequentially assigned to the escalating doses using a standard 3+3 design (**Fig. 1**). Safety and tolerability of giredestrant 100 mg (QD, days 1–28) +palbociclib 125 mg (QD, days 1–21, 21-day on/7-day off schedule) in 28-day cycles was explored in the combination dose-escalation stage. The 90 mg dose originally assigned in the escalation stage was adjusted to 100 mg to account for existing tablet strength. The 100 mg dose was considered equivalent to the 90 mg dose, since only around 10% exposure difference would be expected between the two dose levels.

In the expansion stage, patients received giredestrant QD at 30 mg, 100 mg, and 250 mg, ±LHRH agonist and ±125 mg palbociclib (**Fig. 1**). LHRH agonists (leuprolide acetate/goserelin acetate/triptorelin pamoate) were administered every 4 weeks from cycle 1, day 1 of 28-day cycles according to their prescribing information in premenopausal patients. Only one patient received giredestrant 250 mg +LHRH agonist.

A cohort was dedicated to close evaluation of potential cardiac effects; patients received giredestrant 100 mg monotherapy and underwent 24-hour Holter HR monitoring and exercise tolerance testing prior to starting study drug and again after 8 (+3) days of treatment. Once cardiac assessments were completed, patients continued on single-agent giredestrant 100 mg or giredestrant 100 mg +palbociclib 125 mg per physician's choice for the study duration. The giredestrant 100 mg dose was evaluated in the cardiac evaluation cohort to increase the likelihood of observing relevant cardiac effects, bradycardia being a dose-dependent AE (32). All patients were treated until PD, unacceptable toxicity, withdrawal of consent, or study termination. Enrollment for the 250 mg dose was halted based on a clinical development decision to explore lower dose levels. A second cohort dedicated to evaluating potential cardiac effects was not enrolled based upon review of the favorable safety data from the first cardiac cohort.

Assessments

The primary objective was to evaluate the safety and tolerability of giredestrant when administered as a single agent or in combination with palbociclib, including estimation of the MTD (or MAD), assessed by the following endpoints: occurrence and severity of AEs, including dose-limiting toxicities (DLTs), with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 (33) and changes in targeted vital signs.

The pharmacokinetic objectives were to evaluate the pharmacokinetics of giredestrant as a single agent following single- and multiple-dose treatment, and to characterize the giredestrant, palbociclib, and LHRH agonist pharmacokinetic profiles when giredestrant was administered in combination with palbociclib and/or an LHRH agonist.

The activity objective was to make a preliminary assessment of giredestrant antitumor activity, assessed by objective response rate (ORR; complete/partial response on two consecutive occasions ≥ 4 weeks apart), clinical benefit rate (CBR; percentage of patients achieving confirmed complete response/partial response/first occurrence of PD after 24 weeks of study treatment), and duration of response (DOR; time from first occurrence of a documented objective response until first observation of PD/death from any cause). These were determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Tumor assessments were performed approximately every 8 weeks from cycle 1, day 1 and every 3 months after cycle 12 whenever PD was suspected, as well as at the end of treatment.

Additional objectives were to identify a recommended phase II dose for giredestrant, and to perform an exploratory evaluation of pharmacodynamic response with [^{18}F]-fluoroestradiol positron emission tomography (FES-PET) in a subset of patients in single-agent dose escalation cohorts. For these patients, recent prior use of tamoxifen (within 2 months) and fulvestrant (within 6 months) was not allowed. Change in FES uptake was assessed at cycle 2 (day 3; 18–24 hours after dosing) and quantified as the mean percent change from baseline in background-corrected maximum standardized uptake value measured in up to

five FES-avid lesions. Disease in the liver and some areas of the gastrointestinal tract was considered unevaluable in the FES analysis because of confounding normal physiologic uptake of the tracer.

ESR1 mutation status in circulating tumor DNA (ctDNA) was centrally determined from plasma samples collected at baseline prior to any study treatment; at cycle 1, day 15; and at cycle 2, day 1 using the BEAMing digital PCR assay (Sysmex Inostics, Baltimore, Maryland). *ESR1* mutations were defined as nucleotide substitutions that result in the following amino acid changes: E380Q, S463P, V534E, P535H, L536H/P/Q/R, Y537C/N/S, and D538G.

Statistical analysis

Approximately 30 patients were planned to be enrolled in the single-agent dose-escalation stage, with an additional three receiving giredestrant 100 mg +palbociclib 125 mg. The exact number depended upon the observed safety and pharmacokinetic/pharmacodynamic profile according to the dose-escalation rules. Approximately 220 patients were planned to be enrolled in this study.

For safety analyses, the population included enrolled patients who received ≥ 1 dose of study medication. Safety data were analyzed based on the patient's assigned dose level. All AEs reported during the AE reporting period were considered treatment-emergent. Safety data for patients who received 90 mg single-agent giredestrant in the dose-escalation stage were combined with those for patients receiving 100 mg single-agent giredestrant in the dose-expansion stage, and the data are presented for single-agent giredestrant \pm LHRH agonist, single-agent giredestrant 30 mg (the recommended phase II dose), and giredestrant 100 mg \pm palbociclib 125 mg and \pm LHRH agonist. Safety data for patients in the cardiac evaluation cohort are included within either the single-agent or combination cohorts, where appropriate. For pharmacokinetic analyses, patients with an evaluable post-dose pharmacokinetic sample and estimable pharmacokinetic parameters in the giredestrant 100 mg monotherapy cohort and giredestrant 100 mg +palbociclib 125 mg combination cohorts were included. For activity analyses, ORRs and CBRs were summarized by dose level and cohort.

Data availability

Phase I studies are not in scope of the Roche global policy on data sharing. Qualified researchers may submit an enquiry through the data request platform, Vivli, <https://vivli.org/ourmember/roche/>; however, this does not guarantee that the data can be shared. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification.

The datasets for this study can be shared via the Vivli platform; however, for Phase I studies there will normally be a delay between receiving a request and the ability to fulfill the request to comply with approval of the product/indication.

Results

Patients

Between November 27, 2017, and January 28, 2021, 175 patients were enrolled. Data cutoff was September 17, 2021. Demographics and baseline characteristics are shown in **Table 1** (Representativeness of study participants is shown in Supplementary Table S1). Across all single-agent cohorts, 111 patients were included at all dose levels. At data cutoff, 19 patients (17.1%) were still on study treatment. A total of 93 patients (83.8%) discontinued giredestrant, mostly due to PD (86 [77.5%]) and none due to an AE. Giredestrant-related AEs occurred in 72 patients (64.9%), leading to giredestrant dose modifications/interruptions in five (4.5%). Patients received a median of 6.0 giredestrant cycles (range: 1–39), remained on treatment for a median of 5.6 months (1–36), and the mean dose intensity was 97.5% (standard deviation, 6.0).

Sixty-four patients were included in the giredestrant 100 mg +palbociclib ±LHRH agonist cohort; 37 (57.8%) discontinued giredestrant: 34 due to PD (53.1%), one due to an AE (grade 3 QT prolongation), and one due to grade 5 breast cancer progression. Thirty-six

patients (56.3%) discontinued palbociclib, primarily due to PD (32 [50.0%]). Three (4.7%) discontinued palbociclib due to an AE (neutropenia, arthritis bacterial, QT prolongation). For giredestrant, patients received a median of 14.0 cycles (range: 1–38) and remained on treatment for a median of 12.8 months (0–34); the mean dose intensity was 94.0% (standard deviation, 14.3). A total of 37 patients (57.8%) missed ≥ 1 dose. For palbociclib, patients received a median of 14.0 cycles (range: 1–38) and remained on treatment for a median of 12.6 months (0–34); the mean dose intensity was 90.9% (standard deviation, 11.4). In the cardiac evaluation cohort, 20 patients were included. The median age was 59 years (range: 45–72).

Safety

One hundred eleven patients in the single-agent cohorts were analyzed for safety; 41 were analyzed in the giredestrant 30 mg cohort; and 64 in the giredestrant 100 mg +palbociclib \pm LHRH agonist cohort.

No patients experienced DLTs and the MTD was not reached.

In the single-agent cohorts, 95 patients (85.6%) experienced ≥ 1 AE (Supplementary Table S2). Across all giredestrant single-agent cohorts 17 (15.3%) patients had dose interruptions and three (2.7%) had dose reductions. Giredestrant-related AEs occurred in 72 patients (64.9%), leading to giredestrant dose interruption in five (4.5%), with four of these patients also having a dose reduction. No giredestrant-related AEs led to giredestrant withdrawal (Supplementary Table S2). The most frequently reported AEs assessed as related to giredestrant by the investigator ($\geq 5\%$ of patients) were fatigue (18 [16.2%]), arthralgia (13 [11.7%]), nausea (11 [9.9%]), bradycardia (nine [8.1%]), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increase (eight [7.2%]), diarrhea (seven [6.3%]), hot flush (seven [6.3%]), constipation (six [5.4%]), dyspepsia (six [5.4%]), and dry mouth (six [5.4%]). Most of the frequently reported AEs were grade 1 or 2 in maximum severity. Grade 3 or 4 AEs were reported in five patients: increase of ALT transaminases (one [0.9%]), AST/transaminases (one [0.9%]), diarrhea (one [0.9%]), fatigue (one [0.9%]), and hypertension (one [0.9%]). Serious AEs (SAEs), both related and

unrelated, occurred in 11 patients (9.9%). The only SAE reported in ≥ 2 patients was pleural effusion (two [1.8%]). SAEs were considered unrelated to giredestrant, except grade 2 transient ischemic attack in one patient in the 30 mg cohort, and grade 3 fatigue in one patient in the 100 mg cohort. Fatal AEs occurred in two patients (1.8%) and were considered unrelated to giredestrant: one patient in the 30 mg cohort died from a malignant pleural effusion associated with PD from a new second primary malignancy (squamous cell carcinoma), and another in the 100 mg cohort died from duodenal ulcer perforation that occurred after discontinuation of giredestrant due to PD and start of a new line of treatment with paclitaxel (Supplementary Table S2).

In the giredestrant 30 mg single-agent cohort, 34 patients (82.9%) experienced ≥ 1 AE (Supplementary Table S2). Giredestrant-related AEs occurred in 28 (68.3%), leading to giredestrant dose modifications/interruptions in three (7.3%), and no giredestrant withdrawals (Supplementary Table S2). The most frequently reported AEs assessed as related to giredestrant by the investigator ($\geq 5\%$ of patients) were fatigue (six [14.6%]), arthralgia (six [14.6%]), and nausea (six [14.6%]), dyspepsia (five [12.2%]), dry mouth (four [9.8%]), and diarrhea (three [7.3%]), vomiting (three [7.3%]), and myalgia (three [7.3%]). Most were grade 1, except in some patients who experienced grade 2 fatigue (four [9.8%]), and arthralgia (one [2.4%]), dyspepsia (one [2.4%]), and vomiting (one [2.4%]). SAEs occurred in five patients (12.2%) and were considered unrelated to giredestrant by the investigator, except the grade 2 transient ischemic attack in one patient (2.4%) which resolved within 24 hours.

In the giredestrant 100 mg +palbociclib \pm LHRH agonist cohort, 63 patients (98.4%) experienced ≥ 1 AE (Supplementary Table S2). Giredestrant-related AEs occurred in 38 (59.4%), leading to giredestrant dose modification/interruption in three (4.7%), and giredestrant withdrawal in one (1.6%) (Supplementary Table S2). The most frequently reported AEs assessed as related to giredestrant by the investigator ($\geq 5\%$ of patients) were bradycardia (15 [23.4%]), diarrhea (five [7.8%]), photopsia (four [6.3%]), blurred vision (four [6.3%]), visual impairment (four [6.3%]), nausea (four [6.3%]), and neutropenia (four [6.3%]).

Of these, most were grade 1, except grade 2 nausea in one patient (1.6%), grade 2 neutropenia in three patients (4.7%), and grade 3 neutropenia in one patient (1.6%). All events of photopsia were reported as grade 1, non-serious, and described as "flashes" or "flashes of light." All events were reported as either recovered or recovering without dosing changes. Two events were also reported as related to palbociclib.

All events of visual impairment were reported as grade 1 and non-serious. One event was specifically described as "visual auras" and one as "strobing both eyes." No other events were specifically described. One event was also reported as related to palbociclib.

SAEs occurred in 13 patients (20.3%). Neutropenia/neutrophil count decrease (four patients [6.3%]) was the only SAE reported in ≥ 2 patients. SAEs were considered unrelated to giredestrant except grade 3 QT prolongation (one [1.6%]). A total of five patients (7.8%) experienced palbociclib-related SAEs: grade 4 neutropenia (three patients); grade 4 thrombocytopenia (one) and grade 3 febrile neutropenia (one) (Supplementary Table S2). One patient died due to breast cancer progression (mentioned above), which was considered unrelated to giredestrant (Supplementary Table S2).

In the single-agent cohorts (irrespective of study treatment attribution), blurred vision occurred in six patients [5.4%]: photopsia in two [1.8%], and visual impairment in two [1.8%]), whereas in the giredestrant 100 mg +palbociclib \pm LHRH agonist cohort, frequencies of blurred vision (five [7.8%]), photopsia (six [9.4%]), and visual impairment (six [9.4%]) were higher, likely reflecting the known overlapping toxicity with palbociclib. Eye disorders were transient, and only led to dose modifications in two patients (3.1%) in the giredestrant 100 mg +palbociclib \pm LHRH agonist cohort.

Bradycardia frequency was higher in the giredestrant 100 mg +palbociclib \pm LHRH agonist cohort (18 [28.1%]) than in the single-agent cohorts (11 [9.9%], all single-agent cohorts), including the 90/100 mg single-agent cohort (six [10.9%]) (**Table 2**); however, mean changes in HR were similar between these two groups (Supplementary Table S3).

Twenty-six patients (14.9%) had grade 1 bradycardia events. Three grade 2 bradycardia events were reported: one in the giredestrant 250 mg cohort (related to giredestrant, which

occurred after 22 months on treatment and lasted 7 months, resolving approximately 1 month after stopping giredestrant), one in the 30 mg cohort (unrelated to giredestrant: caused by treatment of an episode of atrial fibrillation with beta-blockers and digoxin), and one in the giredestrant 100 mg +palbociclib ±LHRH agonist cohort that was considered related to giredestrant and required giredestrant interruption on day 28. Bradycardia resolved on day 41 and giredestrant was re-started on day 42 without incident. Overall, 34/37 bradycardia events (91.9%) were resolved/resolving at data cutoff; they were of low intensity, clinically manageable, and reversible.

Cardiac evaluation cohort

No clinically significant changes in HR (**Fig. 2A**), blood pressure (**Fig. 2B**), or exercise duration were observed with treatment. Mean exercise duration was 7.16 minutes (standard deviation, 2.34) at baseline and 7.74 minutes (2.84) on-treatment. Exercise intensity was similar before and after starting treatment (mean metabolic equivalent expenditures were 7.52 [standard deviation, 2.81] and 8.68 [2.78], respectively). HR recovery time following exercise was similar before and during treatment, with one patient having an abnormal HR recovery on exercise testing at screening and again during treatment; all other patients had a normal HR recovery both at screening and during treatment. Twenty-four-hour Holter HR monitoring of patients showed a clinically non-significant reduction in HR while patients were on study treatment compared with screening. A similar diurnal variation with a clinically non-significant reduction in HR while patients were on treatment compared with screening was observed and normal sinus rhythm was maintained (**Fig. 2C**).

Activity

In the single-agent cohorts, ORR in patients with measurable disease at baseline was 19.8% (16/81 patients) and CBR was 48.6% (54/111) (**Table 3**). Tumor responses are shown in **Fig. 3A**. Median DOR was 17.5 months (95% confidence interval [CI], 7.5 months–not evaluable) (**Table 3**). Clinical benefit was observed in 6/23 patients (26.1%) previously treated with fulvestrant, 25/72 (34.7%) previously treated with a CDK4/6i, 32/68 (47.1%) previously treated with chemotherapy in the (neo)adjuvant and/or metastatic settings, and

26/52 (50.0%) with baseline *ESR1*-mutated tumors (Supplementary Table S4). Response by specific baseline *ESR1* mutation is shown in Supplementary Fig. S1. A total of 18 patients in the single-agent dose-escalation stage underwent FES-PET scans: 14 had FES-avid disease at baseline (three each at 10 mg and 250 mg; four each at 30 mg and 90 mg), and 11 of the 14 (78.6%) showed complete or near-complete (>90%) suppression of FES uptake relative to background levels, including patients with *ESR1*-mutated tumors (Supplementary Fig. S2). One patient discontinued early from the study (no on-study scan), and three patients had no FES-avid disease at baseline discernable from physiologic uptake; none of these patients achieved clinical benefit. The vast majority of patients (98%) with a detectable *ESR1* mutation at baseline demonstrated a decrease in *ESR1* variant allele frequency at cycle 1, day 15 and/or cycle 2, day 1 upon treatment with single-agent giredestrant (Supplementary Fig. S3). Of these, 65% overall had a reduced *ESR1* variant allele frequency below the limit of detection, with saturation observed at doses of 30 mg and greater (10 mg: 25%; 30 mg: 75%; 90 or 100 mg: 62%; 250 mg: 67%), and with a higher rate observed in patients who achieved clinical benefit regardless of dose (no clinical benefit: 54%; clinical benefit: 74%).

In the giredestrant 30 mg single-agent cohort, ORR in patients with measurable disease at baseline was 30.0% (9/30 patients), and CBR was 53.7% (22/41) (**Table 3**). Median DOR was not reached (95% CI, 7.5 months–not evaluable) (**Table 3**). Clinical benefit was observed in 3/8 patients (37.5%) previously treated with fulvestrant, 11/27 (40.7%) previously treated with a CDK4/6i, 11/20 (55.0%) previously treated with chemotherapy in the (neo)adjuvant and/or metastatic settings, and 13/21 (61.9%) with baseline *ESR1*-mutated tumors (Supplementary Table S4).

In the giredestrant 100 mg +palbociclib ±LHRH agonist cohort, ORR in patients with measurable disease at baseline was 48.2% (27/56 patients) and CBR was 81.3% (52/64) (**Table 3**). Tumor responses are shown in **Fig. 3B**. Median DOR was not reached (95% CI, 17.4 months–not evaluable) (**Table 3**). Clinical benefit was observed in 3/5 patients (60.0%) previously treated with fulvestrant, 4/5 (80.0%) previously treated with a CDK4/6i, 42/53

(79.2%) previously treated with chemotherapy in the (neo)adjuvant and/or metastatic settings, and 18/18 (100%) with baseline *ESR1*-mutated tumors (Supplementary Table S4).

Decreases in *ESR1* variant allele frequencies were more pronounced in the combination cohort, with 83% of patients with a baseline *ESR1* mutation having no detectable levels of mutated *ESR1* at cycle 2, day 1 (Supplementary Fig. S3).

No clinically relevant drug–drug interaction was observed between palbociclib and giredestrant (Supplementary Table S5), and thus no dose adjustment was needed for giredestrant in combination with palbociclib.

Discussion

In this phase Ia/b study of single-agent giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer, giredestrant was well tolerated; the observed safety profile of the combination of giredestrant and palbociclib was consistent with the known safety profile of the individual drugs at all dose levels tested, including the 30 mg phase III dose. All-grade and grade 3/4 AEs, and SAEs, were more frequent in the giredestrant 100 mg +palbociclib ±LHRH agonist cohort than in the single-agent cohorts, mainly due to hematologic toxicities of palbociclib. No DLTs were observed and the MTD was not reached. Bradycardia has been reported with other SERDs, including camizestrant (34), H3B-6545 (35), and amcenenestrant (36); however, the mechanism of bradycardia is unknown.

Bradycardia is a dose-dependent adverse reaction of giredestrant. In the single-agent cohorts, the incidence of bradycardia was numerically higher at doses of 90/100 mg (6/55 [10.9%]) and 250 mg (2/9 [22.2%]) than that at 30 mg (3/41 [7.3%]). All bradycardia events were low grade, with no SAEs reported at any dose level. Thus, the 30 mg dose was chosen for further evaluation. The frequency of bradycardia was higher in the giredestrant 100 mg +palbociclib ±LHRH agonist cohort (18/64 [28.1%]) than in the corresponding 90/100 mg single-agent cohort (6/55 [10.9%]). However, the mean changes in HR by time on study were similar in these two groups. The reasons for this are unclear, but there is not an obvious more pronounced effect on HR in the giredestrant 100 mg +palbociclib ±LHRH

agonist cohort. The bradycardia observed with giredestrant is generally asymptomatic, and the protocol did not mandate reporting changes in vital signs as AEs, unless they were accompanied by clinical symptoms, required intervention, resulted in change of study treatment, or were otherwise considered clinically significant. It is possible that the early discovery of the safety signal for bradycardia and resulting protocol amendment encompassing evaluation of cardiac effects led to greater awareness, and hence greater reporting of this asymptomatic event.

Once the safety signal of bradycardia at doses of 100 mg and above was observed, the protocol was amended to provide an in-depth evaluation of cardiac effects in a dedicated cohort with 24-hour Holter HR monitoring and exercise stress testing. Patients who received 100 mg giredestrant showed a clinically non-significant reduction in HR with maintenance of normal sinus rhythm; exercise stress testing demonstrated no effects on the ability to exercise or duration of exercise, and no effects on blood pressure. The clinical results are reassuring as the decrease in HR observed with the 100 mg dose was modest and not associated with impact on physical activity or clinical symptoms.

In addition to bradycardia, visual disturbances observed in this study have also been observed with camizestrant; in SERENA-1, these affected 53% of treated patients (34). This has not been reported with other oral SERDs, and the mechanism is unknown. In our study, small numbers of ocular AEs were reported among the single-agent cohorts which were not considered attributable to giredestrant. Larger numbers of ocular AEs were seen in the giredestrant 100 mg +palbociclib ±LHRH agonist cohort, consistent with the palbociclib product labeling (which states that eye disorders are common (37)). Similarly, when looking at ocular toxicity irrespective of causality, the incidence of ocular AEs in the single-agent cohorts was consistent with that seen at baseline but was increased relative to baseline in the palbociclib cohort. AEs of interest include blurred vision (5.4% across giredestrant cohorts vs. 7.8% in the palbociclib combination cohort); photopsia (1.8% vs. 9.4%) and visual impairment (1.8% vs. 9.4%). None of these AEs were reported in the 250 mg cohort; therefore, there was no obvious correlation between these AEs and dose. In addition, the

phase I GO40987 study (27), phase II aceLERA Breast Cancer study (38), and phase II coopERA Breast Cancer study (29, 39) have not reported eye disorders as SAEs and these were not classified as identified or potential risks associated with giredestrant. Eye disorders reported as related to giredestrant were grade 1/2 and non-serious. However, since eye disorders are listed as common on the palbociclib label, these increases are likely due to palbociclib.

Encouraging clinical activity was observed with single-agent giredestrant at all dose levels and patient subgroups, including across patients who received a range of prior treatment types such as chemotherapy, CDK4/6is, and fulvestrant. Activity in patients with *ESR1*-mutated tumors was notable, showing that an ET resistance mechanism commonly observed in the clinic was overcome. FES-PET data demonstrated target engagement and robust reduction in ER activity.

Given that maximal clinical benefit was observed at the 30 mg dose or higher, and that bradycardia was more frequent at doses greater than 30 mg, this dose was selected for further evaluation in phase II/III studies. Although ORR appeared greater at the 30 mg dose compared to higher doses, the confidence intervals were overlapping, suggesting this was a result of chance. In this disease setting, CBR may be a more informative efficacy endpoint given the biology of ER-positive breast cancer which typically has a slower disease course and high incidence of non-measurable disease due to bone involvement. Here, CBRs were comparable. Pharmacodynamic evaluations support the choice of the 30 mg dose, as evidenced by the FES-PET findings and change in *ESR1* ctDNA showing high target engagement at 30 mg, not further enhanced at higher doses. Additionally, in the phase I GO40987 study in the postmenopausal, neoadjuvant setting, giredestrant monotherapy showed pharmacodynamic activity consistent with a 30 mg dose achieving maximal ER inhibition (27).

Additional clinical benefit was achieved with giredestrant in combination with palbociclib 125 mg (\pm LHRH agonist) compared with giredestrant monotherapy, with more patients with confirmed complete or partial responses in the giredestrant 100 mg +palbociclib \pm LHRH

agonist cohort. In addition, the median DOR for the giredestrant 100 mg +palbociclib ±LHRH agonist cohort was longer than in the single-agent cohorts. Clinical benefit was observed across the clinically relevant subgroups.

Palbociclib steady-state maximum and minimum concentrations observed in this study were consistent with previous reports (40), indicating that giredestrant did not appear to have a clinically relevant impact on palbociclib exposures. Exposures for giredestrant in combination with palbociclib were generally comparable to those observed with single-agent giredestrant. In contrast to amcenestrant (41), no dose adjustment was needed when giredestrant was given in combination with palbociclib.

Strengths of this study include its large sample size for a phase Ia/b study (175 patients) and inclusion of both pre- and postmenopausal women. The study was conducted globally across the USA, Europe, Asia, and Australia. In addition, it explored a wide range of dose levels, including a dose-expansion stage at three dose levels in the single-agent cohorts, and with palbociclib to determine the appropriate dose for further study, which was determined to be 30 mg given the more tolerable safety profile and similar activity.

A limitation of this study is that enrollment was limited to patients who had prior prolonged response to ET. Prior knowledge about the safety profile of giredestrant may have led to bias in the reporting of cardiac AEs such as bradycardia. Results obtained for the study endpoints may not be applicable to patients from other regions that were not studied.

Overall, results were consistent with the evaluation of giredestrant in the neoadjuvant early breast cancer setting (27, 39). In the phase I GO40987 study, giredestrant monotherapy showed a promising impact on tumor cell proliferation (Ki67) after 14 days of treatment and no discontinuations due to AEs (27). This was consistent with the results of the phase II coopERA Breast Cancer study, which evaluated activity of giredestrant ±palbociclib in the neoadjuvant setting, and demonstrated superior antiproliferative activity of giredestrant 30 mg compared with anastrozole after 2 weeks of treatment; this superiority was maintained following addition of palbociclib (29, 39). While the phase II aceLERA Breast Cancer study, which compared efficacy and safety of giredestrant versus physician's choice of endocrine

monotherapy in the advanced setting, did not meet its primary endpoint (investigator-assessed progression-free survival), giredestrant showed a numerical improvement, which was more pronounced in patients with *ESR1*-mutated tumors (38). The continued investigation of giredestrant as a single agent in the locally advanced setting is warranted as it is expected to have superior efficacy to currently available SERDs, e.g., fulvestrant, based on preclinical data (25). Similarly, and as seen in coopERA Breast Cancer in the clinical setting (39), clinical data suggest that giredestrant combined with palbociclib may have superior efficacy to currently approved ET–palbociclib combinations (42-45).

Giredestrant is one of several oral SERDs that are being evaluated in clinical trials. Results from the phase Ia/b GO39932 study demonstrate that giredestrant has the potential to provide a well-tolerated, clinically active treatment in patients who have progressed on prior ET, for which there is a high unmet need. As a class, next-generation SERDs may offer a new therapeutic choice for patients with ER+ breast cancer (19, 46), both as monotherapy and in combination with standard-of-care treatment for ER+ breast cancer (elacestrant is now FDA-approved for patients with *ESR1*-mutant tumors based on the EMERALD trial (19)). Giredestrant has shown superior potency compared with other SERDs, and displays nearly full ER occupancy, including in patients with *ESR1*-mutated tumors (25). There are other mechanisms of endocrine resistance beyond *ESR1* mutations, and combinations with novel SERDs may be an option for many patients. For example, the phase III evERA Breast Cancer study will assess giredestrant in combination with everolimus (47), while MORPHEUS Breast Cancer (NCT04802759) will investigate a range of therapies. Giredestrant continues to be assessed in ER+ breast cancer in an ongoing phase III, randomized study of single-agent giredestrant in the HER2-negative early breast cancer treatment setting (lidERA Breast Cancer) (48), as well as in the HER2-negative metastatic setting in persevERA Breast Cancer (49). Finally, in the HER2-positive metastatic setting, giredestrant is being evaluated in heredERA Breast Cancer (50).

Acknowledgments

This study was funded by Genentech, Inc., South San Francisco, California. Komal L. Jhaveri of Memorial Sloan Kettering Cancer Center was also funded by NIH grant P30 CA008748. We thank all the patients who participated in the study, and their families, the investigators, clinicians, and research staff at the 23 centers in five countries. S. Loi is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. Support for third-party writing assistance for this manuscript, furnished by Laura Pérez-Pachón PhD, on behalf of Health Interactions in London, UK, was provided by F. Hoffmann-La Roche Ltd.

This work was supported by Genentech, Inc., South San Francisco, California (no grant number applicable). The funder was involved in the study design, provision of study drugs, protocol development, regulatory and ethics approvals, safety monitoring, data collection, data analysis, data interpretation, and writing of the report, in collaboration with the study authors. All authors had full access to all study data and had final responsibility for the decision to submit for publication.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **2021**;71:209-49.
2. Freeland A, Brown LJ, Parker A, Segara D, Portman N, Lau B, *et al.* Molecular biomarkers for contemporary therapies in hormone receptor-positive breast cancer. *Genes (Basel)* **2021**;12:285.
3. Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. *World J Biol Chem* **2015**;6:231-9.
4. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. *Pharmacol Ther* **2018**;186:1-24.
5. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, *et al.* Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med* **2018**;379:1926-36.
6. Slamon DJ, Neven P, Chia SKL, Jerusalem GHM, De Laurentiis M, Im S-A, *et al.* Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). *J Clin Oncol* **2021**;39:Abstract 1001.
7. Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, *et al.* Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. *Breast Cancer Res : BCR* **2021**;23:87.
8. Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. *Ther Adv Med Oncol* **2015**;7:304-20.
9. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med* **2011**;62:233-47.

10. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, *et al.* Emergence of constitutively active estrogen receptor- α mutations in pretreated advanced estrogen receptor-positive breast cancer. *Clinical Cancer Res* **2014**;20:1757-67.
11. Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. *Breast Cancer Res* **2021**;23:85.
12. Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. *Cancer* **2019**;125:3714-28.
13. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, *et al.* Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol* **2016**;34:2961-8.
14. Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, *et al.* Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. *Ann Oncol* **2018**;29:145-53.
15. Lu Y, Liu W. Selective estrogen receptor degraders (SERDS): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer. *J Med Chem* **2020**;63:15094-114.
16. Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, *et al.* Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. *Cell* **2019**;178:949-63.e18.
17. Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, *et al.* Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. *Expert Opin Investig Drugs* **2022**;31:515-29.
18. Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, *et al.* VERONICA: randomized phase 2 study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors - efficacy, safety, biomarker results. *Clinical Cancer Res* **2022**;28:3256-67.

19. Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, *et al.* Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. *Journal Clin Oncol* **2022**;40:3246-56.
20. Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. *J Clin Oncol* **2016**;34:816-24.
21. Hagen KB, Aas T, Kvaløy JT, Sjøiland H, Lind R. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: a 5-year prospective study. *Breast* **2019**;44:52-8.
22. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, *et al.* Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol* **2010**;28:4594-600.
23. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, *et al.* Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* **2012**;366:520-9.
24. Metcalfe C, Zhou W, Guan J, Blake RA, De Bruyn T, Giltnane JM, *et al.* GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibility in vivo. *Cancer Res* **2020**;80:Abstract 3406.
25. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, *et al.* GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. *J Med Chem* **2021**;64:11841-56.
26. Hurvitz SA, Park YH, Bardia A, Quiroga V, López-Valverde V, Steinseifer J, *et al.* Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative,

- untreated early breast cancer (ER+/HER2- eBC): interim analysis of the randomised, open-label, phase II coopERA BC study. *Ann Oncol* **2021**;32:Abstract LBA14 and associated oral presentation.
27. Moore HM, Boni V, Bellet M, Heras BBDL, Cortés MG, Oakman C, *et al.* Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC). *J Clin Oncol* **2021**;39:Abstract 577 and associated poster presentation.
 28. Metcalfe C, Ingalla E, Blake R, Chang J, Daemen A, De Bruyn T, *et al.* GDC-9545: a novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. *Cancer Res* **2019**;79:(suppl 4; abstr P5-04-7).
 29. Hurvitz SA, Quiroga V, Park YH, Bardia A, López-Valverde V, Steinseifer J, *et al.* Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: primary analysis of the randomized, open-label, phase II coopERA breast cancer study. *Cancer Res* **2022**;82:Abstract PD13-06.
 30. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, *et al.* Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. *J Clin Oncol* **2020**;38:1346-66.
 31. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, *et al.* Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med* **2018**;142:1364-82.
 32. Jhaveri KL, Boni V, Sohn J, Villanueva-Vásquez R, Bardia A, Schmid P, *et al.* Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). *J Clin Oncol* **2021**;39:Abstract 1017.

33. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). [cited 2022 Oct 24]. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
34. Hamilton EP, Oliveira M, Banerji U, Hernando C, Garcia-Corbacho J, Armstrong A, *et al*. A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer. *J Clin Oncol* **2020**;38:Abstract 1024 and associated poster presentation.
35. Johnston SRD, Pluard TJ, Wang JS, Hamilton EP, Juric D, Scholz CR, *et al*. Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. *J Clin Oncol* **2021**;39:Abstract e13025.
36. Bardia A, Chandarlapaty S, Linden HM, Ulaner GA, Gosselin A, Cartot-Cotton S, *et al*. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. *Nat Commun* **2022**;13:4116.
37. Pfizer Europe MA EEIG. Ibrance (palbociclib). Summary of Product Characteristics. [cited 2022 Oct 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf.
38. Martin M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, *et al*. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase 2, randomised, open-label aceLERA BC study. *Ann Oncol* **2022**;33:S633-S4. Abstract 211MO and associated mini-oral.
39. Fasching PA, Bardia A, Quiroga V, Park Y, Blancas I, Alonso J, *et al*. Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal

- women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): final analysis of the randomized, open-label, international phase 2 coopERA BC study. *J Clin Oncol* **2022**;40:Abstract 589.
40. Center for Drug Evaluation and Research (CDER). Clinical pharmacology and biopharmaceutics review(s). Application number: 207103Orig1s000. [cited 2022 Oct 24]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103orig1s000clinpharmr.pdf.
 41. Chandarlapaty S, Linden HM, Neven P, Petrakova K, Bardia A, Kabos P, *et al*. AMEERA-1: phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). *J Clin Oncol* **2021**;39:Abstract 1058 and associated poster presentation.
 42. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, *et al*. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol* **2015**;16:25-35.
 43. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, *et al*. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* **2015**;373:209-19.
 44. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, *et al*. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med* **2016**;375:1925-36.
 45. Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, *et al*. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). *J Clin Oncol* **2016**;34:Abstract 507.

46. Linden HM, Campone M, Bardia A, Ulaner GA, Gosselin A, Doroumian S, *et al.* A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1. *Cancer Res* **2021**;81:Abstract PD8-08 and associated poster presentation.
47. Mayer E TS, Brufsky A, Gradishar W, Jhaveri K, Martin M, Luca M, Vidal G, Cortazar P, Feldman M, Day BM, Rugo H. OT2-01-07: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer). In.OT2-01-07: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer); 2022.
48. Bardia A, Schmid P, Harbeck N, Rimawi MF, Hurvitz SA, Loi S, *et al.* Lidera breast cancer: a phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC). *Cancer Res* **2022**;82:(suppl 4; abstr OT2-11-09).
49. Turner NC, Jhaveri KL, Bardia A, Niikura N, Dieras V, Barrios CH, *et al.* persevERA Breast Cancer (BC): phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2- LA/mBC). *J Clin Oncol* **2021**;39:(suppl 15; abstr TPS1103).
50. Kuemmel S H-WC, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Shivhare M, Restuccia E, O'Shaughnessy J. heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab

for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer. *Cancer Res* **2023**;TBC:OT2-03-1 (abstr).

Tables

Table 1. Demographics and baseline characteristics of the intention-to-treat population.

Data are number of patients (%) unless specified.

Abbreviations: CDK4/6, cyclin-dependent kinase 4/6; ECOG, Eastern Cooperative Oncology Group; LHRH, luteinizing hormone releasing hormone; NOS, not otherwise specified.

^aPrior use of CDK4/6 inhibitor was allowed in the cardiac evaluation cohort (five patients within this cohort had received a prior CDK4/6 inhibitor).

^bPrior use of chemotherapy in any line of therapy.

	giredestrant 10 mg (n = 6)	giredestrant 30 mg (n = 41)	giredestrant 90/100 mg ±LHRH (n = 55)	giredestrant 250 mg ±LHRH (n = 9)	All giredestrant doses (n = 111)	giredestrant 100 mg +palbociclib 125 mg ±LHRH (n = 64)	All patients (N = 175)
Age, mean years (standard deviation)	58.7 (10.6)	60.1 (11.4)	57.6 (10.8)	57.4 (11.2)	58.6 (11.0)	56.9 (10.9)	58.0 (10.9)
Ethnicity							
Hispanic/Latino	0	2 (4.9%)	2 (3.6%)	0	4 (3.6%)	1 (1.6%)	5 (2.9%)
Not Hispanic/Latino	5 (83.3%)	37 (90.2%)	49 (89.1%)	8 (88.9%)	99 (89.2%)	62 (96.9%)	161 (92.0%)
Not stated	1 (16.7%)	2 (4.9%)	0	0	3 (2.7%)	0	3 (1.7%)
Unknown	0	0	4 (7.3%)	1 (11.1%)	5 (4.5%)	1 (1.6%)	6 (3.4%)
Race							
American Indian/Alaska Native	0	0	1 (1.8%)	0	1 (0.9%)	0	1 (0.6%)
Asian	0	12 (29.3%)	13 (23.6%)	4 (44.4%)	29 (26.1%)	11 (17.2%)	40 (22.9%)
White	6 (100%)	28 (68.3%)	37 (67.3%)	1 (11.1%)	75 (67.6%)	53 (82.8%)	128 (73.1%)
Unknown	0	1 (2.4%)	4 (7.3%)	0	6 (5.4%)	0	6 (3.4%)
Mean weight at baseline, kg (standard deviation)	62.87 (8.64)	69.94 (16.79)	65.37 (15.60)	65.60 (18.57)	66.99 (16.01)	67.86 (14.43)	67.31 (15.41)
ECOG performance status score at baseline							
0	4 (66.7%)	24 (58.5%)	37 (67.3%)	6 (66.7%)	71 (64.0%)	39 (60.9%)	110 (62.9%)
1	2 (33.3%)	17 (41.5%)	18 (32.7%)	3 (33.3%)	40 (36.0%)	25 (39.1%)	65 (37.1%)
Bone-only disease at baseline							
Yes	1 (16.7%)	6 (14.6%)	12 (21.8%)	1 (11.1%)	20 (18.0%)	11 (17.2%)	31 (17.7%)
No	5 (83.3%)	35 (85.4%)	43 (78.2%)	8 (88.9%)	91 (82.0%)	53 (82.8%)	144 (82.3%)
Visceral disease at baseline							
Yes	3 (50.0%)	30 (73.2%)	35 (63.6%)	4 (44.4%)	72 (64.9%)	45 (70.3%)	117 (66.9%)
No	3 (50.0%)	11 (26.8%)	20 (36.4%)	5 (55.6%)	39 (35.1%)	19 (29.7%)	58 (33.1%)
Measurable disease at baseline							
Yes	4 (66.7%)	30 (73.2%)	41 (74.5%)	6 (66.7%)	81 (73.0%)	56 (87.5%)	137 (78.3%)
No	2 (33.3%)	11 (26.8%)	14 (25.5%)	3 (33.3%)	30 (27.0%)	8 (12.5%)	38 (21.7%)
Number of lines of prior metastatic therapies, median (range)	1.50 (0–3.0)	1.00 (0–2.0)	1.00 (0–2.0)	1.00 (0–2.0)	1.00 (0–3.0)	1.00 (0–2.0)	1.00 (0–3.0)
Prior use of fulvestrant							
Yes	2 (33.3%)	8 (19.5%)	13 (23.6%)	0	23 (20.7%)	5 (7.8%)	28 (16.0%)
No	4 (66.7%)	33 (80.5%)	42 (76.4%)	9 (100%)	88 (79.3%)	59 (92.2%)	147 (84.0%)
Prior use of CDK4/6 inhibitor							
Yes	4 (66.7%)	27 (66.9%)	34 (61.8%)	7 (77.8%)	72 (64.9%)	5 (7.8%) ^a	77 (44.0%)
No	2 (33.3%)	14 (34.1%)	21 (38.2%)	2 (22.2%)	39 (35.1%)	59 (92.2%)	98 (56.0%)
Baseline <i>ESR1</i> mutation status							
No mutation detected	2 (33.3%)	19 (46.3%)	32 (58.2%)	3 (33.3%)	56 (50.5%)	40 (62.5%)	96 (54.9%)
Mutation detected	4 (66.7%)	21 (51.2%)	21 (38.2%)	6 (66.7%)	52 (46.8%)	18 (28.1%)	70 (40.0%)
Unknown	0	1 (2.4%)	2 (3.6%)	0	3 (2.7%)	6 (9.4%)	9 (5.1%)
Prior chemotherapy in the metastatic setting							
Yes	2 (33.3%)	8 (19.5%)	8 (14.5%)	1 (11.1%)	19 (17.1%)	13 (20.3%)	32 (18.3%)
No	4 (66.7%)	33 (80.5%)	47 (85.5%)	8 (88.9%)	92 (82.9%)	51 (79.7%)	143 (81.7%)
Prior use of chemotherapy ^b							
Yes	5 (83.3%)	20 (48.8%)	36 (65.5%)	7 (77.8%)	68 (61.3%)	53 (82.8%)	121 (69.1%)
No	1 (16.7%)	21 (51.2%)	19 (34.5%)	2 (22.2%)	43 (38.7%)	11 (17.2%)	54 (30.9%)
Histologic subtype							
Ductal	4 (66.7%)	31 (77.5%)	42 (80.8%)	7 (77.8%)	84 (78.5%)	56 (88.9%)	140 (82.4%)
Lobular	2 (33.3%)	6 (15.0%)	10 (19.2%)	2 (22.2%)	20 (18.7%)	7 (11.1%)	27 (15.9%)
NOS	0	2 (5.0%)	0	0	2 (1.9%)	0	2 (1.2%)
Other	0	1 (2.5%)	0	0	1 (0.9%)	0	1 (0.6%)
Nuclear grade (pleomorphism)							
Grade 1	0	3 (7.5%)	5 (9.8%)	0	8 (7.5%)	2 (3.3%)	10 (6.0%)
Grade 2	1 (16.7%)	12 (30.0%)	18 (35.3%)	4 (44.4%)	35 (33.0%)	23 (37.7%)	58 (34.7%)
Grade 3	2 (33.3%)	10 (25.0%)	9 (17.6%)	2 (22.2%)	23 (21.7%)	20 (32.8%)	43 (25.7%)
Unknown	3 (50.0%)	15 (37.5%)	19 (37.3%)	3 (33.3%)	40 (37.7%)	16 (26.2%)	56 (33.5%)

Classification of breast cancer, distant metastasis at initial diagnosis							
MX	0	5 (12.2%)	4 (7.5%)	1 (11.1%)	10 (9.3%)	3 (4.8%)	13 (7.6%)
M0	2 (50.0%)	23 (56.1%)	38 (71.7%)	7 (77.8%)	70 (65.4%)	50 (79.4%)	120 (70.6%)
M1	2 (50.0%)	13 (31.7%)	11 (20.8%)	1 (11.1%)	27 (25.2%)	10 (15.9%)	37 (21.8%)

Table 2. Most common ($\geq 10\%$) treatment-emergent adverse events of any grade in the safety-evaluable population.

Data are number of patients (%).

Abbreviation: LHRH, luteinizing hormone-releasing hormone.

	giredestrant 10 mg (n = 6)	giredestrant 30 mg (n = 41)	giredestrant 90/100 mg ±LHRH (n = 55)	giredestrant 250 mg ±LHRH (n = 9)	All single-agent giredestrant doses (n = 111)	giredestrant 100 mg +palbociclib 125 mg ±LHRH (n = 64)	All patients (N = 175)
Arthralgia	2 (33.3%)	10 (24.4%)	11 (20.0%)	2 (22.2%)	25 (22.5%)	14 (21.9%)	39 (22.3%)
Fatigue	2 (33.3%)	7 (17.1%)	12 (21.8%)	3 (33.3%)	24 (21.6%)	21 (32.8%)	45 (25.7%)
Back pain	2 (33.3%)	7 (17.1%)	13 (23.6%)	1 (11.1%)	23 (20.7%)	14 (21.9%)	37 (21.1%)
Nausea	2 (33.3%)	9 (22.0%)	10 (18.2%)	0	21 (18.9%)	13 (20.3%)	34 (19.4%)
Diarrhea	1 (16.7%)	5 (12.2%)	8 (14.5%)	2 (22.2%)	16 (14.4%)	18 (28.1%)	34 (19.4%)
Constipation	2 (33.3%)	6 (14.6%)	6 (10.9%)	0	14 (12.6%)	15 (23.4%)	29 (16.6%)
Cough	1 (16.7%)	3 (7.3%)	9 (16.4%)	1 (11.1%)	14 (12.6%)	14 (21.9%)	28 (16.0%)
Pain in extremity	0	3 (7.3%)	8 (14.5%)	1 (11.1%)	12 (10.8%)	7 (10.9%)	19 (10.9%)
Anemia	0	5 (12.2%)	4 (7.3%)	2 (22.2%)	11 (9.9%)	16 (25.0%)	27 (15.4%)
Bradycardia	0	3 (7.3%)	6 (10.9%)	2 (22.2%)	11 (9.9%)	18 (28.1%)	29 (16.6%)
Dizziness	3 (50.0%)	4 (9.8%)	3 (5.5%)	1 (11.1%)	11 (9.9%)	9 (14.1%)	20 (11.4%)
Vomiting	0	7 (17.1%)	4 (7.3%)	0	11 (9.9%)	7 (10.9%)	18 (10.3%)
Headache	2 (33.3%)	4 (9.8%)	4 (7.3%)	0	10 (9.0%)	8 (12.5%)	18 (10.3%)
Asthenia	0	4 (9.8%)	4 (7.3%)	0	8 (7.2%)	13 (20.3%)	21 (12.0%)
Alopecia	0	2 (4.9%)	3 (5.5%)	0	5 (4.5%)	15 (23.4%)	20 (11.4%)
Neutropenia	1 (16.7%)	2 (4.9%)	2 (3.6%)	0	5 (4.5%)	52 (81.3%)	57 (32.6%)
Thrombocytopenia	2 (33.3%)	1 (2.4%)	1 (1.8%)	1 (11.1%)	5 (4.5%)	13 (20.3%)	18 (10.3%)

Table 3. Clinical benefit and confirmed best overall response rates in the safety-evaluable population and selected subgroup responders (objective response rate).

Data are number of patients (%) unless specified. Responders are patients with best confirmed response of CR or PR by RECIST v1.1. 95% CI for rates were constructed using Clopper-Pearson method. Patients were classified as “SD” if assessment was at least 6 weeks from baseline/study entry. Patients were classified as “NE” if all post-baseline response assessments were reported as NE, or SD assessment occurred within 6 weeks from baseline/study entry. Patients were classified as “missing” if no post-baseline response assessments were available. Clinical benefit includes patients with confirmed CR, PR, or the first occurrence of disease progression observed on or after 24 weeks. Note that one patient from the giredestrant 100 mg ±LHRH agonist cohort is currently counted as one of the patients who had SD as the best overall response as well as having clinical benefit; however, this patient had the target lesion removed and therefore became response non-evaluable per RECIST v1.1.

Abbreviations: CI, confidence interval; CR, complete response; NE, not evaluable; LHRH, luteinizing hormone-releasing hormone; ORR, objective response rate; PD, disease progression; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

^aClinical-benefit-evaluable population is defined as patients with confirmed CR, PR, or patients who discontinued from study, or patients staying on the treatment for at least 24 weeks since cycle 1, day 1 of giredestrant.

^bCensored observation.

	giredestrant 10 mg (n = 6)	giredestrant 30 mg (n = 41)	giredestrant 90/100 mg ±LHRH (n = 55)	giredestrant 250 mg ±LHRH (n = 9)	All giredestrant doses (n = 111)	giredestrant 100 mg +palbociclib 125 mg ±LHRH (n = 64)	All patients (N = 175)
Clinical benefit by investigator in clinical-benefit-evaluable ^a patients	1 (16.7%)	22 (53.7%)	28 (50.9%)	3 (33.3%)	54 (48.6%)	52 (81.3%)	106 (60.6%)
ORR (95% CI)	1 (16.7%) (0.42–64.12)	9 (22.0%) (10.56–37.61)	6 (10.9%) (4.11–22.25)	0 (0–33.63)	16 (14.4%) (8.47–22.35)	27 (42.2%) (29.94–55.18)	43 (24.6%) (18.39–31.64)
ORR in patients with measurable disease at							

baseline	1 (25.0%)	9 (30.0%)	6 (14.6%)	0	16 (19.8%)	27 (48.2%)	43 (31.4%)
Total n	4	30	41	6	81	56	137
(95% CI)	(0.63–80.59)	(14.73–49.40)	(5.57–29.17)	(0–45.93)	(11.73–30.09)	(34.66–61.97)	(23.73–39.87)
CR	0	0	0	0	0	6 (9.4%)	6 (3.4%)
PR	1 (16.7%)	9 (22.0%)	6 (10.9%)	0	16 (14.4%)	21 (32.8%)	37 (21.1%)
SD	2 (33.3%)	12 (29.3%)	27 (49.1%)	5 (55.6%)	46 (41.4%)	28 (43.8%)	74 (42.3%)
Non-CR/non-PD	0	6 (14.6%)	5 (9.1%)	0	11 (9.9%)	2 (3.1%)	13 (7.4%)
PD	2 (33.3%)	14 (34.1%)	13 (23.6%)	3 (33.3%)	32 (28.8%)	6 (9.4%)	38 (21.7%)
NE	0	0	0	0	0	0	0
Missing	1 (16.7%)	0	4 (7.3%)	1 (11.1%)	6 (5.4%)	1 (1.6%)	7 (4.0%)
Duration of response (months)							
Median	12.0	NE	17.5	NE	17.5	NE	22.8
95% CI	NE	(7.5, NE)	(3.7, NE)	NE	(7.5, NE)	(17.4, NE)	(14.9, NE)
Range	12–12	3 ^b –14 ^b	3–34 ^b	NE	3–34 ^b	4 ^b –32 ^b	3–34 ^b

Figure legends

Figure 1.

Study design.

giredestrant: PO QD days 1–28 of each 28-day cycle.

Palbociclib: 125 mg PO QD.

LHRH: Q4W at the label recommended dose (the schedule for goserelin acetate; the only LHRH used in this study despite leuprolide acetate and triptorelin pamoate being allowed).

Abbreviations: LHRH, luteinizing hormone—releasing hormone; MAD, maximum administered dose; MTD, maximum tolerated dose; PO QD, oral once daily; Q4W, once every 4 weeks.

^aThe 90 mg dose originally assigned in the escalation stage was adjusted to 100 mg to account for existing tablet strength and considered equivalent to the 90 mg dose.

Figure 2.

Boxplots of exercise test results for heart rate (A), diastolic and systolic blood pressure (B), and mean plot of electrocardiogram results from Holter monitor by visit and real time (C).

For Figures 2A and 2B: Raw assessment results are summarized at each time point. All measures at study treatment were collected after 7 days of single-agent dosing (giredestrant 100 mg).

For Figure 2C: Average of the observations is taken if there are multiple observations per real time point. Plot starts with real time when 24-hour Holter HR monitoring started for screening or study treatment, respectively. For example, starting point of D1H9 on screening means Holter monitoring started at 9 am on the day of screening. All measures at study treatment were collected after 7 days of single-agent dosing (giredestrant 100 mg).

Abbreviations: bpm, beats per minute; CCOD, clinical cutoff date; CRF, case report form; D, day; H, hour; HR, heart rate.

Figure 3.

Waterfall plot of best percent change from baseline in tumor sum of diameters in the safety-evaluable population: single-agent cohorts (A) and giredestrant 100 mg +palbociclib ±luteinizing hormone-releasing hormone agonist cohorts (B).

Cohorts of best confirmed overall response are shown on the plot.

Abbreviations: CR, complete response; *ESR1m*, *ESR1* mutant; LHRH, luteinizing hormone-releasing hormone; NA, not assessed; NE, not evaluable; NON, non-CR/non-PD; PD, disease progression; PR, partial response; SD, stable disease.

Figure 1






Figure 2

A




B



C

Screening



Study treatment





Figure 3

A



B

